Table 1.

Description of participants

Participant	Age range (years)	Type of DM	Duration of DM range (years)	Treatment of DM	Type of MI
1	70–79	2	10–19	OHG	NSTEMI
2	50–59	2	10–19	OHG/In	NSTEMI
3	80–89	2	10–19	OHG/In	Acute MI unspecified
4	40–49	2	0–9	OHG	NSTEMI
5	70–79	2	20–29	OHG	NSTEMI
6	50–59	2	10–19	In	NSTEMI
8	70–79	2	10–19	OHG	Acute MI unspecified
10	70–79	2	10–19	OHG/diet	STEMI
11	50–59	1	10–19	In	STEMI
13	60–69	2	NR	OHG/In	NSTEMI
14	80–89	2	0–9	OHG	STEMI
15	60–69	2	0–9	OHG	STEMI
16	70–79	2	0–9	OHG	NSTEMI
17	60–69	2	>10	OHG+	NSTEMI
18	70–79	2	NR		Acute MI unspecified
19	60–69	1	40–49	In	NSTEMI
20	80–89	2	0–9	OHG	NSTEMI
21	70–79	2	>10	OHG	Acute MI unspecified/cardiac arrest
22	60–69	2	NR	OHG	NSTEMI
23	60–69	2	0–9	OHG	Acute MI unspecified/cardiac arrest
24	70–79	2	10–19	OHG	NSTEMI/cardiac arrest
25	70–79	2	>25	OHG/In	STEMI
26	50–59	2	10–19	OHG/In	STEMI
27	70–79	2	0–9	OHG	STEMI/cardiac arrest
29	50–59	1	30–39	In	NSTEMI
30	60–69	2	10–19	OHG+/In	NSTEMI
31	40–49	2	0–9	OHG	STEMI
32	80–89	2	>20	OHG+	NSTEMI
33	60–69	2	10–19	OHG+	STEMI
34	60–69	2	10–19	OHG	STEMI
35	50–59	2	0–9	Diet	NSTEMI
36	40–49	2	20–29	OHG/In	NSTEMI
37	60–69	2	0–9		NSTEMI
38	70–79	2	10–19	OHG	NSTEMI
39	50–59	2	10–19	OHG/In	NSTEMI
40	40–49	1	30–39	OHG/In	NSTEMI
41	90–99	2	30–39	In	NSTEMI
42	50–59	2	0–10	OHG	NSTEMI
43	60–69	2	10–19	OHG	NSTEMI

Cases 7, 9, 12 and 28 are not included as they did not meet study criteria.

Treatment key: OHG, oral hypoglycaemics (eg, metformin/glicazide and so on); In, insulins; OHG+, oral hypoglycaemics+other drugs, for example, gliptins/glitazones.

DM, diabetes mellitus; MI, myocardial infarction; NSTEMI, non-ST elevated MI; STEMI, ST elevated MI.